Plant-based diet for people with chronic kidney disease stage 3 or 4
Tests a mostly plant-based diet in adults with moderate chronic kidney disease.
Plain-language title generated from the registry record
Registry title: Feasibility, Safety and Efficacy of a Predominantly Plant-based Diet in an Asian Population With Chronic Kidney Disease
Key facts
- Where
- Singapore, SingaporeSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 79 years old?
Source: NCT07544524, who can take part
Where in Singapore
- Changi General HospitalSingapore, SingaporeTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Changi General Hospital
- Trial code
- NCT07544524
- Record updated
- 22 April 2026
- Original description
This two-year follow up, single-center, open-label, feasibility study will recruit outpatients from the Renal Medicine Clinic at Changi General Hospital. Eligible patients with Stage 3 or 4 CKD will be assigned preferencebased to either a plant-based diet intervention (intake of at least 50% protein from plant sources) with regular dietitian counselling and follow up, or a control group receiving dietitian counselling for general CKD dietary advice without information on percentage of plant-based foods. Six monthly assessments will include estimated glomerular filtration rate (eGFR), serum potassium, nutritional markers, and other relevant biochemical parameters. Quality of life and dietary adherence will be evaluated through questionnaires and food frequency records. This study will evaluate primarily, the feasibility of a plant-based diet in the Singaporean context. Secondarily it will evaluate its safety in terms of incidence of hyperkalaemia, and benefit in terms of improvement in acidosis.Read full original descriptionShow less
Feasibility, Safety and Efficacy of a Predominantly Plant-based Diet in an Asian Population With Chronic Kidney Disease
This two-year follow up, single-center, open-label, feasibility study will recruit outpatients from the Renal Medicine Clinic at Changi General Hospital. Eligible patients with Stage 3 or 4 CKD will be assigned preferencebased to either a plant-based diet intervention (intake of at least 50% protein from plant sources) with regular dietitian counselling and follow up, or a control group receiving dietitian counselling for general CKD dietary advice without information on percentage of plant-based foods. Six monthly assessments will include estimated glomerular filtration rate (eGFR), serum potassium, nutritional markers, and other relevant biochemical parameters. Quality of life and dietary adherence will be evaluated through questionnaires and food frequency records. This study will evaluate primarily, the feasibility of a plant-based diet in the Singaporean context. Secondarily it will evaluate its safety in terms of incidence of hyperkalaemia, and benefit in terms of improvement in acidosis.
Other exploratory outcomes will include (1) preliminary efficacy of plant-based diets on CKD progression (measured by eGFR decline); (2) risk of nutritional deficiencies such as vitamin D, B12 and iron; and (3) impact on other biochemical parameters of CKD.
Inclusion: Age 21-79 (Only adults who can give consent will be recruited. Older adults aged 80 are not included to reduce the risk of confounding due to age-related frailty, sarcopenia and multimorbidity. Additionally, older adults may have different nutritional needs and energy requirements); CKD stage 3-4 (baseline eGFR 15-60ml/min/1.72m2 for the past 6 months); Willingness to see a dietitian and follow either a standard CKD diet or a predominantly plant-based CKD diet; On maximum tolerated dose of ACE-inhibitors (Angiotensin converting enzyme inhibitors) or ARB (Aldosterone receptor blocker) as determined by Renal Physician in charge; Able to provide informed consent.
Exclusion: Transplant patients (who will tend to have more variable trajectories, immunosuppression related challenges etc which may make this study less feasible); Patients who were on any special diet for at least 1 month prior to recruitment (inclusive of; Those who have seen a dietitian for CKD previously; Exclude patients with acute kidney injury (AKI) in the past 6 months prior to study (unstable renal disease; Patients with severe ischemic heart disease, decompensated liver cirrhosis, malabsorptive diseases or malignancy; Patients with glomerulonephritis, genetic kidney disease or polycystic kidney disease; Baseline serum potassium 5.0 and above; Age <21 or >/= 80 (Avoid growing children who have different nutritional requirements and advanced elderly who are more likely to have malnutrition or sarcopenia due to other pre-existing causes); Pregnant or lactating patients (who have different nutritional requirements than the standard CKD patients); long-term vegans or vegetarians) - excluded because they already have stable dietary habits; Patients with BMI <18.5 or >40; Patients who are unable to modify their diet due to socio-economic issues.